- Home
- ACIU vs ADCT Comparison
ACIU vs ADCT Comparison
Compare ACIU & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- ADCT
- Stock Information
- Founded
- ACIU 2003
- ADCT 2011
- Country
- ACIU Switzerland
- ADCT Switzerland
- Employees
- ACIU N/A
- ADCT N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- ADCT Health Care
- Exchange
- ACIU Nasdaq
- ADCT Nasdaq
- Market Cap
- ACIU 332.4M
- ADCT 224.3M
- IPO Year
- ACIU 2016
- ADCT 2020
- Fundamental
- Price
- ACIU $2.67
- ADCT $1.98
- Analyst Decision
- ACIU Strong Buy
- ADCT Strong Buy
- Analyst Count
- ACIU 2
- ADCT 5
- Target Price
- ACIU $12.00
- ADCT $8.00
- AVG Volume (30 Days)
- ACIU 132.5K
- ADCT 1.7M
- Earning Date
- ACIU 11-05-2024
- ADCT 11-07-2024
- Dividend Yield
- ACIU N/A
- ADCT N/A
- EPS Growth
- ACIU N/A
- ADCT N/A
- EPS
- ACIU N/A
- ADCT N/A
- Revenue
- ACIU $48,505,404.00
- ADCT $70,717,000.00
- Revenue This Year
- ACIU $85.33
- ADCT $6.58
- Revenue Next Year
- ACIU $80.69
- ADCT $11.78
- P/E Ratio
- ACIU N/A
- ADCT N/A
- Revenue Growth
- ACIU 4097200.00
- ADCT N/A
- 52 Week Low
- ACIU $2.25
- ADCT $1.45
- 52 Week High
- ACIU $5.14
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- ACIU 27.22
- ADCT 44.05
- Support Level
- ACIU $2.63
- ADCT $1.93
- Resistance Level
- ACIU $3.07
- ADCT $2.18
- Average True Range (ATR)
- ACIU 0.15
- ADCT 0.40
- MACD
- ACIU -0.04
- ADCT -0.02
- Stochastic Oscillator
- ACIU 8.96
- ADCT 10.65
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.